Low volume, Gleason 3 + 4 = 7 disease: is active surveillance a realistic option?

It would be easy to misinterpret (or at least “over-interpret”) a recent paper from the group at Johns Hopkins about the pathological outcomes of men initially diagnosed with very low-, low-, or “favorable” intermediate-risk localized disease and treated by immediate radical prostatectomy. … READ MORE …

Updated PIVOT data seem to support recent AUA/ASTRO/SUO guidelines

A new article in this week’s New England Journal of Medicine has given us follow-up data from the PIVOT trial of radical prostatectomy vs. simple observation in treatment of localized prostate cancer. … READ MORE …

Radio-guided salvage surgery for recurrent prostate cancer

A recent article (in German in Der Urologe) has discussed the early use of PSMA-radio-guided surgery (PSMA-RGS) for targeted resection of localized prostate cancer recurrence. … READ MORE …

Genomic prediction of risk for biochemical relapse post-surgery

Yet another genetic/genomic test (this one developed by Metamark Genetics) may have value in the assessment of risk for biochemical progression after first-line surgery for prostate cancer. … READ MORE …

Sexual rehabilitation after surgical treatment for localized prostate cancer: nine formal recommendations

Two recent articles by Salonia et al. (from the Fourth International Consultation for Sexual Medicine or ICSM 2015) have provided us with a series of nine recommendations to clinicians regarding sexual rehabilitation after radical prostatectomy for localized prostate cancer. … READ MORE …

Aggressive, neoadjuvant androgen ablation prior to surgery in higher risk prostate cancer patients

The development of drugs like abiraterone acetate and enzalutamide has stimulated new research into the use of such agents early on, in combination with first-line therapy, to see if it can affect the outcomes for men with high-risk and unfavorable intermediate-risk prostate cancer. … READ MORE …

Letters to the Editor on interpretation of data from the ProtecT trial

In September last year, Hamdy et al. published the initial results of the ProtecT trial — a trial designed to compare overall outcomes at 10 years among > 1,600 men diagnosed with low- and intermediate-risk, localized prostate cancer and randomized to treatment by surgery, by external beam radiation therapy, or by active monitoring (a very basic form of active surveillance). … READ MORE …